This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DexCom's (DXCM) Stelo Glucose Biosensor Receives FDA Approval
by Zacks Equity Research
DexCom's (DXCM) Stelo receives FDA clearance, which makes it the first FDA-approved glucose biosensor to be available over the counter.
The Zacks Analyst Blog Highlights The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works
by Zacks Equity Research
The Ensign Group, Cardinal Health, Consolidated Water, Colgate-Palmolive and American Water Works are included in this Analyst Blog.
4 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like PPC, SUN, CAH and TXT are seeing price strength and have a high chance of carrying the momentum forward.
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
by Zacks Equity Research
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
Best Growth Stocks to Buy for March 6th
by Zacks Equity Research
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 6, 2023.
3 Top-Ranked Stocks to Buy for Stability
by Derek Lewis
Targeting low-beta stocks can provide a valuable layer of stability for portfolios. After all, defense wins ballgames.
Reasons to Retain Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test
by Zacks Equity Research
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio
by Zacks Equity Research
Ecolab's (ECL) focus on R&D raises optimism about the stock.
Lantheus' (LNTH) DEFINITY Approved by FDA for Pediatric Use
by Zacks Equity Research
Lantheus' (LNTH) receipt of the expanded indication for DEFINITY is likely to address unmet medical needs of pediatric patients.
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
by Zacks Equity Research
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease
by Zacks Equity Research
BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
5 Defensive Stocks to Buy as Consumer Sentiment Dips Again
by Ritujay Ghosh
Investing in defensive stocks like The Ensign Group (ENSG), Cardinal Health (CAH), Consolidated Water (CWCO), Colgate-Palmolive (CL) and American Water Works, Inc. (AWK) is a safe bet as consumer sentiment is once again sinking.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Boston Scientific (BSX) Grows IC Business With New FDA Nod
by Zacks Equity Research
The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.
ICON (ICLR) Gains From Strategic Deals, New Innovations
by Zacks Equity Research
ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.
Reasons to Add ShockWave Medical (SWAV) to Your Portfolio Now
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Cardinal Health and Humana have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cardinal Health and Humana have been highlighted as Zacks Bull and Bear of the Day.
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
by Zacks Equity Research
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space
by Zacks Equity Research
Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.
GE HealthCare's (GEHC) New Launch to Enhance Precision Care
by Zacks Equity Research
GE HealthCare's (GEHC) latest innovations are likely to provide patient-centered care for a broad patient population in a variety of clinical settings.
Best Growth Stocks to Buy for March 4th
by Zacks Equity Research
PAGS, CAH and NVDA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on March 4, 2023.
Bull of the Day: Cardinal Health (CAH)
by Derek Lewis
Better-than-expected quarterly results have helped drive Cardinal Health's bullish move over the last year, exceeding our consensus EPS estimates by an average of 15% across its last four releases.
Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities
by Zacks Equity Research
Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.